| Next 10 |
Ad
PDSB News and Press PDS Biotechnology Corporation
News | PDS Biotechnology Corporation (NYSE:PDSB)
-
2023-06-06 09:49:10 ET Following a ~31% decline in the previous session, the shares of PDS Biotechnology ( NASDAQ: PDSB ) rose ~9% in the pre-market Tuesday as Cantor Fitzgerald and H.C. Wainwright defended the stock arguing that the selloff was overdone. H.C. Wainwright analyst...
-
2023-06-06 08:37:27 ET Brera Holdings ( BREA ) +104% Acquires Strategic Stake in Manchester United PLC. Hoth Therapeutics ( HOTH ) +24% Announces Positive Preclinical Results of HT-ALZ treatment for Alzheimer's Disease. GitLab ( GTLB ) +27% Q1 earnings ca...
-
FLORHAM PARK, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that the Company will be hosting a conference cal...
-
2023-06-05 13:06:50 ET Gainers: Forza X1 ( FRZA ) +164% . Sono Group ( SEV ) +123% . Chijet Motor Company ( CJET ) +62% . CIRCOR International ( CIR ) +51% . Timber Pharmaceuticals ( TMBR ) +44% . TOP Financial Group ( TOP ...
-
2023-05-27 03:40:53 ET Summary PDS Biotech's Phase 2 study shows potential breakthrough in treating HPV16-positive head and neck cancer. The study shows a 87.1% 12-month survival rate for ICI naive patients, nearly doubling typical rates from similar treatments. Despite higher...
-
2023-05-26 10:05:44 ET Gainers: Elevation Oncology ( ELEV ) +58% . Arcus Biosciences ( RCUS ) +26% . Healthcare Triangle ( HCTI ) +17% . PDS Biotechnology ( PDSB ) +16% . NEXGEL ( NXGL ) +12% . Losers: Tilray Brands (...
-
2023-05-26 06:53:18 ET PDS Biotechnology ( NASDAQ: PDSB ) added ~20% pre-market Friday after announcing interim Phase 2 data for its lead candidate PDS0101 in combination with Merck's ( NYSE: MRK ) anti-PD-1 therapy, Keytruda in certain patients with human papillomavirus...
-
Interim data being presented at ASCO 2023 Annual Meeting Demonstrated median progression-free survival (PFS) of 10.4 months Demonstrated 12-month overall survival (OS) rate of 87.1% A disease control rate (disease stabilization or tumor shrinkage) of 70.6% Median o...
-
2023-05-19 15:00:19 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...
-
FLORHAM PARK, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced the completion of enrollment in the immune che...
Stock Information
PDS Biotechnology Corporation Company Name:
PDSB Stock Symbol:
NYSE Market:
PDS Biotechnology Corporation Website:
Get PDSB Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
